Aezea (cenersen) / Eleos - LARVOL DELTA

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - P1; N=9; Terminated; Sponsor: Eleos, Inc.; N=18 ➔ 9; Enrolling by invitation ➔ Terminated; Company went out of business

Enrollment change • Trial termination • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide, and rituximab for high risk CLL (Leuk Lymphoma) - P2, N=20; The CRR & ORR were 18% & 53% respectively; Median PFS and OS were 5.3 and 10.6 months, respectively; The most common serious AEs were neutropenia and thrombocytopenia

P2 data • Hematological Malignancies